NASDAQ:ACIU - AC Immune Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.50
  • Forecasted Upside: 136.05 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.99
▲ +0.12 (1.75%)

This chart shows the closing price for ACIU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AC Immune Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACIU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACIU

Analyst Price Target is $16.50
▲ +136.05% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for AC Immune in the last 3 months. The average price target is $16.50, with a high forecast of $17.00 and a low forecast of $16.00. The average price target represents a 136.05% upside from the last price of $6.99.

This chart shows the closing price for ACIU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in AC Immune. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2021SVB LeerinkReiterated RatingBuy$17.00Low
3/24/2021HC WainwrightBoost Price TargetBuy$11.00 ➝ $16.00High
9/24/2020HC WainwrightReiterated RatingBuy$11.00High
12/10/2019HC WainwrightReiterated RatingBuy$8.00 ➝ $11.00Medium
7/12/2019HC WainwrightSet Price TargetBuy$8.00Low
2/4/2019HC WainwrightReiterated RatingBuy$8.00Low
2/1/2019UBS GroupDowngradeBuy ➝ NeutralMedium
1/24/2019HC WainwrightReiterated RatingBuy$18.00Low
1/4/2019UBS GroupInitiated CoverageBuy ➝ Buy$16.00High
11/12/2018SVB LeerinkInitiated CoverageOutperform$18.00High
8/9/2018HC WainwrightSet Price TargetBuy$18.00Low
5/3/2018Credit Suisse GroupSet Price TargetHold$14.00High
4/5/2018HC WainwrightInitiated CoverageBuy$18.00High
3/23/2018Credit Suisse GroupDowngradeOutperform ➝ Neutral$18.00 ➝ $14.00High
7/19/2017Credit Suisse GroupSet Price TargetBuy$18.00High
5/31/2017Credit Suisse GroupSet Price TargetBuy$18.00Low
12/13/2016Jefferies Financial GroupReiterated RatingBuy$25.00N/A
12/13/2016Credit Suisse GroupReiterated RatingOutperform$18.00N/A
11/26/2016SVB LeerinkReiterated RatingOutperformN/A
10/18/2016SVB LeerinkInitiated CoverageOutperform$22.00N/A
10/18/2016Credit Suisse GroupInitiated CoverageOutperform$18.00N/A
10/18/2016Jefferies Financial GroupInitiated CoverageBuy$25.00N/A
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
AC Immune logo
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Read More

Today's Range

Now: $6.99
Low: $6.80
High: $7.02

50 Day Range

MA: $7.11
Low: $6.20
High: $8.24

52 Week Range

Now: $6.99
Low: $4.42
High: $12.61

Volume

312,737 shs

Average Volume

1,194,009 shs

Market Capitalization

$507.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of AC Immune?

The following Wall Street research analysts have issued research reports on AC Immune in the last year: HC Wainwright, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for ACIU.

What is the current price target for AC Immune?

2 Wall Street analysts have set twelve-month price targets for AC Immune in the last year. Their average twelve-month price target is $16.50, suggesting a possible upside of 136.1%. SVB Leerink LLC has the highest price target set, predicting ACIU will reach $17.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $16.00 for AC Immune in the next year.
View the latest price targets for ACIU.

What is the current consensus analyst rating for AC Immune?

AC Immune currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACIU will outperform the market and that investors should add to their positions of AC Immune.
View the latest ratings for ACIU.

What other companies compete with AC Immune?

How do I contact AC Immune's investor relations team?

AC Immune's physical mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company's listed phone number is (121) 693-9121 and its investor relations email address is [email protected] The official website for AC Immune is www.acimmune.com.